BioSpace News Archive

A new study reveals the benefits of reducing exposure to a common chemical for reducing the risk of diabetes.

The revolutionary sam® sustained acoustic medicine device from ZetrOZ Systems will be featured in a technology demonstration at the 15th annual TOBI Orthobiologic Symposium, June 20-22, at Caesar’s Palace in Las Vegas.

Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a Consultancy Agreement with BIO-CONVERT in Denmark.

Findings from the SURMOUNT-OSA, a study of tirzepatide in patients with obstructive sleep apnea and obesity, were announced, revealing significant improvements in both sleep apnea severity and related metabolic issues.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).

Singular Genomics Systems, Inc. announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock.

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) has received notification from the European Commission (“EC”) that it has approved FRUZAQLA®.

Avidity Biosciences, Inc. announced that on June 20, 2024, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 173,300 shares of its common stock and 86,650 restricted stock units to fourteen new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

Inteleos, a global non-profit healthcare certification organization, announced that its Point-of-Care Ultrasound Certification Academy launched its comprehensive Maternal Fetal Health Certification, with its new Obstetrics 2nd/3rd Trimester Clinical Certificate.